Comparison Between Efficacy And Safety Of Rituximab Plus CHOP(R-CHOP) And CHOP Regimen On Patients With Stage Ⅲ And Ⅳ Diffuse Large B-cell Lymphoma

ObjectiveTo compare the effect and safty of rituximab plus CHOP and CHOP regimen on patients with Stageâ…¢andâ…£Diffuse Large B-cell Lymphoma.Methods31 patients with Stageâ…¢andâ…£Diffuse Large B-cell Lymphoma were studied. They were non-randomly divided into two groups:16 patients were treated with R-CHOP, the others with CHOP. NHL international efficacy assessment and WHO criteria were used to assess the therapeutic and the adverse effects, respectively.ResultsThe overall response rate of R-CHOP group was 87.5%, including 8 CR and 6 PR. That of the CHOP group was 53.3% with 4CR and 4PR. The response rate was significantly higher in R-CHOP group than in CHOP group (P=0.044). The half-year survival rate was 100% in R-CHOP group and 93% in CHOP group, respectively. The half-year PFS rates were 93.75% and 73.3%, respectively. There were no significant differences between half-year survival rates and PFS rates in two groups. (P>0.05). The major side effects in both regimens were gastrointestinal toxicity and mild to moderate myelosuppression, with no significant difference. (P>0.05).ConclusionsComparing with CHOP, rituximab plus CHOP regimen increases the therapeutic efficacy to patients withâ…¢andâ…£Diffuse Large B-cell Lymphoma, and has no significant increase in toxicity.